Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
50.51
+0.47 (+0.94%)
Streaming Delayed Price
Updated: 12:41 PM EDT, Apr 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
36
37
Next >
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare
May 24, 2022
From
Genentech
Via
Business Wire
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
↗
May 23, 2022
Via
Benzinga
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients
↗
May 17, 2022
Via
Benzinga
Current Report: Roche Holding
↗
May 16, 2022
Roche’s price per share was $39.75 as of Friday's market close. One year ago its price was $42.20.
Via
Talk Markets
The OTC Markets' Most Active Securities Welcomes New Names And Experiences A Reshuffle In April
↗
May 13, 2022
Photo by Becca on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. First-quarter 2022 market...
Via
Benzinga
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
↗
May 11, 2022
Roche isn't the only company working on an anti-TIGIT molecule.
Via
Investor's Business Daily
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
↗
May 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer
↗
May 11, 2022
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung...
Via
Benzinga
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
May 11, 2022
From
Genentech
Via
Business Wire
Market Selloff
↗
May 10, 2022
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive.
Via
Talk Markets
Roche Releases More Evrysdi Data For Very Young Infants With SMA
↗
April 29, 2022
Via
Benzinga
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
April 29, 2022
From
Genentech
Via
Business Wire
Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook
↗
April 26, 2022
Via
Benzinga
Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials
↗
April 25, 2022
The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine.
Via
Benzinga
COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook
↗
April 25, 2022
Via
Benzinga
EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs
↗
April 22, 2022
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
↗
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
↗
April 20, 2022
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...
Via
Benzinga
4 Undervalued Biotech Stocks to Add to Your Buy List
↗
April 20, 2022
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.
Via
InvestorPlace
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
↗
April 16, 2022
Let’s pause to consider earlier attempts at hostile takeovers by well-respected and well-financed entities and individuals that — to ransack some Musk-worthy clichés — took off like a rocket ship but...
Via
Talk Markets
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
↗
April 15, 2022
As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.
Via
Benzinga
FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy
↗
April 14, 2022
Via
Benzinga
Volume Springs Back Into The OTC Markets In March – Take A Look At Some Of The Top Movers
↗
April 14, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Trading volume appears to be moving back to OTC Markets...
Via
Benzinga
Read Why Pliant Therapeutics Shares Are Soaring Today
↗
April 13, 2022
Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need.
Via
Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
↗
April 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Via
Benzinga
Healthcare Stocks Lead the Way Up as the Market Fades
↗
April 11, 2022
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions.
Via
Talk Markets
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
↗
April 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
↗
April 08, 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now.
Via
InvestorPlace
How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug
↗
April 08, 2022
Only Medicare patients enrolled in specific studies will receive reimbursement.
Via
Investor's Business Daily
Good and Bad stock news
↗
April 05, 2022
Microsoft is down because of an FTC investigation of its possible anti-competitive moves.
Via
Talk Markets
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
36
37
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
